Replies to post #173 on Fate Therapeutics Inc (FATE)

[NY1972]

allo carts need to make a breakthrough to treat solid tumors. Most allo bios targeting BCMA/CD19 won't survive the bear market. They are still trying to figure out the effective dose and target pts. AUTL and AFMD offer the most promising data IMO

[jondoeuk]

ALLO has dropped the bulk of a cell therapy collaboration with Notch Therapeutics, leaving just one CAR target from the original deal https://www.sec.gov/Archives/edgar/data/1737287/000173728724000003/allo-20240125.htm

Since then, Notch has continued to make progress on iPSC-derived ab CD8+ T-cells https://notchtx.com/wp-content/uploads/2024/04/2024-03-19_AACR-Poster_FINAL_v4.pdf https://notchtx.com/wp-content/uploads/2024/05/2024-05-03_ISCT_Shri_FINAL_PRINT-READY-1.pdf https://notchtx.com/wp-content/uploads/2024/07/2024-06-22_ISSCR_Laura_v5ba.pdf

Interestingly, EZH1 impacts NOTCH signaling and one group showed that knockdown promotes differentiation towards an ab T-cell fate rather than gd T-cells. It also enhanced the antitumour activity https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(22)00295-8